
Edasalonexent Treatment in Young Boys with Duchenne Muscular Dystrophy is Associated with Age-Normative Growth and Normal Adrenal Function

Erika L. Finanger, MD¹; Richard Finkel, MD²; Krista Vandenborne, PT, PhD³; H Lee Sweeney, PhD³; Gihan Tennekoon, MBBS, MRCS, LCRP⁴; Perry Shieh, MD, PhD⁵; Sabrina W. Yum, MD⁴; Maria Mancini, MHP⁶; James MacDougall, PhD⁶; Joanne Donovan, MD, PhD⁶

¹Oregon Health Sciences University, Portland, OR; ²Nemours Children's Health System, Orlando, FL; ³University of Florida Health, Gainesville, FL; ⁴The Children's Hospital of Philadelphia, Philadelphia, PA; ⁵University of California, Los Angeles, Los Angeles, CA; ⁶Catabasis Pharmaceuticals, Boston, MA

NF-ĸB Inhibition and Edasalonexent Mechanism of Action



Donovan et al. J Clin Pharmacol 2017 57:627-639

Study Design and Capsule Swallowing Ability

Yin, et al. Muscle & Nerve 2017 56:759-767

Hammers, et al. JCI Insight 2016 1(21): e90347

Phase 2 Safety Experience

BMI z-Scores

Design of MoveDMD[®], a Phase 1/2 Trial with Open-Label Extension

Study Objectives

- Safety and PK in pediatric patients with DMD
- Proof of concept using MRI to assess changes in muscle health
- Long-term safety and effects on age-appropriate functional measures to enable design of Phase 3 study

Study Population

- Age 4 up to 8th birthday not currently being treated with corticosteroids
- Able to perform timed function tests and MRI

Design

- Phase 1: 1-week open-label to assess safety and PK, with initial assessments of function and MRI
- Off-treatment period of ~6 months prior to Phase 2
- Phase 2: 12-week placebo-controlled period of 67 mg/kg and 100 mg/kg doses of edasalonexent
- Open-label extension up to 150 weeks




Prespecified Analysis Plan

- 12-week placebo controlled period evaluated MRI T2, North Star Ambulatory Assessment, timed-function tests, and safety
- Additional comparison of rates of change during off-treatment control period versus on edasalonexent treatment

Experience with Edasalonexent Demonstrates Ability of 4 to 7-year-old Boys with DMD to Take Soft-gel Capsules in Clinical Trials


- As part of the eligibility criteria, Phase 2 MoveDMD trial required boys to demonstrate ability to swallow at least one capsule size in order to meet eligibility
- → In the Phase 2 MoveDMD trial, 97% of boys screened were able to swallow capsules
- Edasalonexent capsules were well-accepted in boys with DMD
- Site experience, clinical trial personnel confidence and initial capsule size presentation had the most significant impact in selection.
- Age did not appear to be a major determinant of ability to take capsules
- Soft-gel capsules were successfully be used in this phase 2 clinical trial of boys as young as 4 years with appropriate support





In Phase 2 MoveDMD Trial and Open-Label Extension: Safety: Edasalonexent was Well-Tolerated

 Well tolerated for up to 150 weeks 	Treatment-Related Adverse Events >5%	Edasalonexent Overall (N=31)
 Majority of adverse events mild in nature Most common related adverse event was diarrhea, generally mild and transient 	System Organ Class/ Preferred Term	n %
	Subjects with any treatment-emergent adverse event	31 (100%)
	Subjects with any treatment-emergent adverse event related to study treatment	19 (61.3)
	Gastrointestinal disorders	
 No serious adverse events on treatment (one on placebo) 	Diarrhoea	16 (51.6%)
	Abdominal pain upper	7 (22.6%)
	Nausea	3 (9.7%)
 No adverse trends in chemistry and hematology 	Vomiting	3 (9.7%)
	Abdominal discomfort	2 (6.5%)
	Abdominal pain	2 (6.5%)
	Faecal incontinence	2 (6.5%)
	Faeces soft	2 (6.5%)
	Metabolism and nutrition disorders	
	Decreased appetite	4 (12.9%)


Phase 2 Safety Experience	Phase 2 Bone Health and Growth Curves			
In Phase 2 MoveDMD Trial and Open-Label Extension: Safety: Edasalonexent was Well-Tolerated	Potential for Bone Preservation with Edasalonexent	In Phase 2 MoveDMD Trial and Open-Label Extension: Safety: Growth Continues as Expected Compared to Standard Growth Charts		
There was no evidence of adrenal insufficiency for up to 150 weeks, with no clinically significant changes in either cortisol or ACTH	 Unlike glucocorticoids (GC), edasalonexent treatment in a mdx mouse model preserves bone length and bone density In DMD: Bone length Muscle force 	 Boys on edasalonexent grew similarly to growth curves for unaffected boys up to 150 weeks Weight increased by an average of 4.5 lbs/year Height increased by an average of 1.9 inches/year 		
Pituitary gland \longrightarrow ACTH Production \longrightarrow Adrenal Gland \longrightarrow Cortisol Production	Femur Length Cortical Density 20 T 12 T	BMI is typically elevated in these boys and on edasalonexent treatment, BMI trended down		
ACTH Cortisol	16 Image: Comparison of the second	z-Scores Compared to CDC Growth Charts Weight z-Scores Height z-Scores BMI z-Scores		







(3):309-315




GALAXYDMD

Open-label extension

NCT03703882 and NCT03917719

Edasalonexent

Box plot error bars indicate range of values Comparison with CDC growth charts: https://www.cdc.gov/growthcharts/clinical_charts.htm




Conclusion and Acknowledgements

Conclusion

Acknowledgements

- In the Phase 2 MoveDMD trial, treatment with edasalonexent was well-tolerated and associated with favorable growth patterns without negative impact on bone health or adrenal function.
- Edasalonexent has the potential to be disease-modifying in DMD patients and in this Phase 2 trial did not have the adverse effects associated with high-dose steroids.
- An ongoing Phase 3 trial of edasalonexent, PolarisDMD, is fully enrolled and is further assessing safety and efficacy in young boys with DMD.





Site staff

Catabasis team

Thanks to PPMD and MDA for generous grant support for patient travel



Questions? MedInfo@catabasis.com

Disclosures

- Erika Finanger received research support and honoraria from Catabasis Pharmaceuticals, Inc.
- The clinical trial was sponsored by Catabasis Pharmaceuticals, Inc.
- Krista Vandenborne, H. Lee Sweeney, Erika Finanger, Gihan Tennekoon, Perry Shieh, and Sabrina Yum received research support from Catabasis. H. Lee Sweeney, Erika Finanger, and Perry Shieh received honoraria from Catabasis
- Maria Mancini, James MacDougall, and Joanne Donovan are employees or consultants of Catabasis and may hold stock in Catabasis
- Edasalonexent is an investigational agent that is not approved in any territory

Corresponding Author, Joanne Donovan: MedInfo@catabasis.com **Presented at the 2020 MDA Clinical & Scientific Conference**

